Novartis enlists Microsoft to modernize drugs' path to market

Novartis
Novartis has tapped Microsoft's artificial intelligence prowess to advance its drug development platforms from discovery to manufacturing to marketing. (Novartis)

Novartis’ new collaboration with Microsoft leverages artificial intelligence to streamline drug discovery, but the joint effort goes beyond just finding new treatments faster.

From research and manufacturing to clinical trials and marketing, Microsoft’s AI technology will impact Novartis’ entire medicine path to market. Everyone, even those without data science training, will be able to use the solutions to cull Novartis data troves.

“There’s value for every person in the organization to share data, to connect to each other, beyond the research and discovery to manufacturing, even to marketing,” Peter Lee, Microsoft's corporate vice president for AI and research, said in an intro video.

On-Demand Webinar

De-Risking the Solid Form Landscape of an API

This presentation will discuss how predictable stability and solubility can minimize development timelines and cost. Attend to hear about two case studies exemplifying the importance of understanding the hydration space of an API and how hydrate formation may be avoided by development of a robust crystallization procedure.

RELATED: Novartis puts AI on the job to help reps say the right things to the right doctors

The way Novartis sees it, the company is on a path to becoming a “data science company,” Shahram Ebadollahi, Novartis' global head of data science, said by email. And the Microsoft deal figures importantly into that corporate mission. After all, what better way to drive substantial change—and get a jump on competing pharma companies also trying to figure out how to use their reams of health data—than to partner with the original vanguard of tech companies?

The two companies had worked together previously and went through many months of exploration before announcing the deal, Ebadollahi said. It is a “true 50-50 collaboration,” he added.

Novartis is not new to the use of AI, but this collaboration expands beyond previous efforts. Along with revamp of the drug discovery process, for instance, Novartis will use Microsoft AI to review the clinical data from hundreds of its drug studies over the past two decades. The project, called Data42, will mine 2 million patient years of clinical trial data to attempt to uncover new insights, Ebadollahi said.

RELATED: Novartis' Sandoz goes digital from back office to 'not just apps,' therapeutics

“The synergy between Novartis’ global leadership in innovative medicines and Microsoft’s leadership position in Cloud and AI will help us deliver a fundamental transformation in healthcare,” he said. “Together, we will empower the work of healthcare professionals and address some of society’s most challenging healthcare issues for the benefit of as many people as possible.”

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.